The treatment also reduced lower respiratory infections requiring medical attention by more than 60%. Merck plans to discuss ... that only use Trader Joe's products.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim. Clesrovimab ...

Despite Merck & Co. homing in on approval for its infant respiratory syncytial virus (RSV) antibody clesrovimab, Sanofi—which last year won its own nod for its AstraZeneca-partnered RSV ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside ... monoclonal antibody designed to protect infants from respiratory syncytial virus (RSV) disease during their first RSV ...

Merck said its experimental shot designed to protect infants from respiratory syncytial virus showed positive results in a mid- to late-stage trial. The pharmaceutical giant could emerge as a new ...

Welcome to the Merck & Company Q3 sales and earnings conference call. [Operator instructions] This call is being recorded.

Sotatercept is in phase 3 testing as an add-on therapy for PAH, and according to Merck has the potential to become a $3 billion product at peak for PAH, thanks to its to become the first drug for ...